Lerociclib: Experimental Treatment for Epidermal Growth Factor Receptor mutant (EGFRm) Non-Small Cell Lung Cancer (NSCLC)
Scientific rationale and therapeutic potential
Lerociclib is a potent and selective oral CDK4/6 inhibitor designed to block the growth of cancer cells and induce tumor-cell death when combined with other anti-cancer agents, such as Tagrisso®. Lerociclib has the potential to be best-in-class versus other oral CDK4/6 inhibitors.
Preclinical rationale (see: Publications)
- published preclinical data demonstrating lerociclib is more potent and less toxic than other oral CDK4/6 inhibitors in development;
- preclinical data presented at the AACR 2018 annual meeting demonstrated that lerociclib can enhance the efficacy of EGFRi in NSCLC models.
G1 is recruiting patients for a Phase 1b/2 trial in EGFRm NSCLC